Search

Your search keyword '"Correa-Rotter, Ricardo"' showing total 17 results
Start Over Author "Correa-Rotter, Ricardo" Publisher oxford university press (oup)
17 results on '"Correa-Rotter, Ricardo"'

1. The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysis

Author

McEwan, Phil, primary, Gabb, Peter D, additional, Davis, Jason A, additional, Sanchez, Juan Jose Garcia, additional, Sjöström, C David, additional, Barone, Salvatore, additional, Kashioulis, Pavlos, additional, Ouwens, Mario, additional, Cassimaty, Syd, additional, Correa-Rotter, Ricardo, additional, Rossing, Peter, additional, Wheeler, David C, additional, and Heerspink, Hiddo J L, additional

Published
2024
Full Text
View/download PDF

2. #294 Pragmatic literature reviews to populate a patient-level model to project the future clinical burden of CKD in low-and middle-income countries

Author

Correa-Rotter, Ricardo, primary, Ngigi, John, additional, Holt, Steve, additional, Cong, Luong Nguyen, additional, Sanchez, Juan Jose Garcia, additional, Solorzano, Jaime, additional, Goncalves, Susana, additional, Guzek, John, additional, Mitchyn, Markiyan, additional, Webber, Laura, additional, and Retat, Lise, additional

Published
2024
Full Text
View/download PDF

3. #255 PaCE CKD: the impact of caregiving on health states and work productivity in chronic kidney disease: results from an international survey

Author

Sanchez, Juan Jose Garcia, primary, Wu, Mai-Szu, additional, Chadban, Steven, additional, Correa-Rotter, Ricardo, additional, Reichel, Helmut, additional, Elsayed, Hesham, additional, Rangaswami, Janani, additional, Esposito, Ciro, additional, Hull, Richard, additional, Pentakota, Surendra, additional, West, Bronwyn, additional, Kularatne, Thames, additional, and Fifer, Simon, additional

Published
2024
Full Text
View/download PDF

4. #254 PaCE CKD: examining health status and financial burden in patients with chronic kidney disease: assessing the non-clinical burden of disease

Author

Sanchez, Juan Jose Garcia, primary, Reichel, Helmut, additional, Rangaswami, Janani, additional, Esposito, Ciro, additional, Elsayed, Hesham, additional, Wu, Mai-Szu, additional, Hull, Richard, additional, Chadban, Steven, additional, Correa-Rotter, Ricardo, additional, Pentakota, Surendra, additional, West, Bronwyn, additional, Kularatne, Thames, additional, and Fifer, Simon, additional

Published
2024
Full Text
View/download PDF

5. Efficacy and Safety of Dapagliflozin in Patients With Chronic Kidney Disease Across the Spectrum of Frailty

Author

Vart, Priya, primary, Butt, Jawad H, additional, Jongs, Niels, additional, Schechter, Meir, additional, Chertow, Glenn M, additional, Wheeler, David C, additional, Pecoits-Filho, Roberto, additional, Langkilde, Anna Maria, additional, Correa-Rotter, Ricardo, additional, Rossing, Peter, additional, McMurray, John J V, additional, and Heerspink, Hiddo J L, additional

Published
2023
Full Text
View/download PDF

6. #2758 AMBIENT HEAT EXPOSURE AND ESTIMATED GLOMERULAR FILTRATION RATE TRAJECTORY: A POST-HOC ANALYSIS OF THE DAPA-CKD TRIAL

Author

Zhang, Zhiyan, primary, Heerspink, Hiddo Lambers, additional, Chertow, Glenn, additional, Correa-Rotter, Ricardo, additional, Gasparrini, Antonio, additional, Jong, Niels, additional, Langkilde, Anna Maria, additional, Mistry, Malcolm, additional, Mcmurray, John, additional, Rossing, Peter, additional, Toto, Robert, additional, Vart, Priya, additional, Nitsch, Dorothea, additional, Wheeler, David C, additional, and Caplin, Ben, additional

Published
2023
Full Text
View/download PDF

7. Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis

Author

McEwan, Phil, primary, Boyce, Rebecca, additional, Sanchez, Juan Jose Garcia, additional, Sjöström, C David, additional, Stefansson, Bergur, additional, Nolan, Stephen, additional, Correa-Rotter, Ricardo, additional, Rossing, Peter, additional, Chertow, Glenn M, additional, McMurray, John J V, additional, Wheeler, David C, additional, and Heerspink, Hiddo J L, additional

Published
2022
Full Text
View/download PDF

8. MO534: Associations of Haemoglobin Values and Rate of Changes With Mace in the ASCEND-D Randomised Clinical Trial

Author

Obrador, Gregorio, primary, Macdougall, Iain, additional, Johansen, Kirsten, additional, Jha, Vivekanand, additional, Correa-Rotter, Ricardo, additional, Del Vecchio, Lucia, additional, Cases Amenos, Aleix, additional, Robertson, Michele, additional, Mallett, Steve, additional, K. Bailey, Christine, additional, Cobitz, Alexander, additional, and K. Singh, Ajay, additional

Published
2022
Full Text
View/download PDF

9. MO535: Associations of Haemoglobin Values and Rate of Changes With MACE in the ASCEND-ND Randomised Clinical Trial

Author

K. Singh, Ajay, primary, Macdougall, Iain, additional, Johansen, Kirsten, additional, Jha, Vivekanand, additional, Correa-Rotter, Ricardo, additional, Del Vecchio, Lucia, additional, Cases Amenos, Aleix, additional, Robertson, Michele, additional, Mallett, Steve, additional, K. Bailey, Christine, additional, Cobitz, Alexander, additional, and Obrador, Gregorio, additional

Published
2022
Full Text
View/download PDF

10. FC082: Effects of Dapagliflozin in Patients with Chronic Kidney Disease According to Background Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Dose

Author

Lambers Heerspink, Hiddo, primary, Jong, Niels, additional, Stefansson, Bergur, additional, Chertow, Glenn, additional, Maria Langkilde, Anna, additional, Mcmurray, John, additional, Correa-Rotter, Ricardo, additional, Rossing, Peter, additional, Toto, Robert, additional, and Wheeler, David, additional

Published
2022
Full Text
View/download PDF

11. Effects of dapagliflozin on mortality in patients with chronic kidney disease : a pre-specified analysis from the DAPA-CKD randomized controlled trial.

Author

Heerspink, Hiddo J L, Sjöström, C David, Jongs, Niels, Chertow, Glenn M, Kosiborod, Mikhail, Hou, Fan Fan, McMurray, John J V, Rossing, Peter, Correa-Rotter, Ricardo, Kurlyandskaya, Raisa, Stefansson, Bergur V, Toto, Robert D, Langkilde, Anna Maria, Wheeler, David C, Held, Claes, Heerspink, Hiddo J L, Sjöström, C David, Jongs, Niels, Chertow, Glenn M, Kosiborod, Mikhail, Hou, Fan Fan, McMurray, John J V, Rossing, Peter, Correa-Rotter, Ricardo, Kurlyandskaya, Raisa, Stefansson, Bergur V, Toto, Robert D, Langkilde, Anna Maria, Wheeler, David C, and Held, Claes

Abstract

AIMS: Mortality rates from chronic kidney disease (CKD) have increased in the last decade. In this pre-specified analysis of the DAPA-CKD trial, we determined the effects of dapagliflozin on cardiovascular and non-cardiovascular causes of death. METHODS AND RESULTS: DAPA-CKD was an international, randomized, placebo-controlled trial with a median of 2.4 years of follow-up. Eligible participants were adult patients with CKD, defined as a urinary albumin-to-creatinine ratio (UACR) 200-5000 mg/g and an estimated glomerular filtration rate (eGFR) 25-75 mL/min/1.73 m2. All-cause mortality was a key secondary endpoint. Cardiovascular and non-cardiovascular death was adjudicated by an independent clinical events committee. The DAPA-CKD trial randomized participants to dapagliflozin 10 mg/day (n = 2152) or placebo (n = 2152). The mean age was 62 years, 33% were women, the mean eGFR was 43.1 mL/min/1.73 m2, and the median UACR was 949 mg/g. During follow-up, 247 (5.7%) patients died, of whom 91 (36.8%) died due to cardiovascular causes, 102 (41.3%) due to non-cardiovascular causes, and in 54 (21.9%) patients, the cause of death was undetermined. The relative risk reduction for all-cause mortality with dapagliflozin (31%, hazard ratio [HR] [95% confidence interval (CI)] 0.69 [0.53, 0.88]; P = 0.003) was consistent across pre-specified subgroups. The effect on all-cause mortality was driven largely by a 46% relative risk reduction of non-cardiovascular death (HR [95% CI] 0.54 [0.36, 0.82]). Deaths due to infections and malignancies were the most frequently occurring causes of non-cardiovascular deaths and were reduced with dapagliflozin vs. placebo. CONCLUSION: In patients with CKD, dapagliflozin prolonged survival irrespective of baseline patient characteristics. The benefits were driven largely by reductions in non-cardiovascular death.

Published
2021
Full Text
View/download PDF

12. FC 063DAPAGLIFLOZIN DECREASES ALBUMINURIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE WITH AND WITHOUT TYPE 2 DIABETES: INSIGHTS FROM THE DAPA-CKD TRIAL

Author

Jong, Niels, primary, Chertow, Glenn, additional, Hou, Fan Fan, additional, McMurray, John, additional, Correa-Rotter, Ricardo, additional, Rossing, Peter, additional, Sjöström, David, additional, Stefansson, Bergur, additional, Toto, Robert, additional, Langkilde, Anna Maria, additional, Wheeler, David C, additional, and Lambers Heerspink, Hiddo, additional

Published
2021
Full Text
View/download PDF

14. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

Author

Wheeler, David C, primary, Stefansson, Bergur V, additional, Batiushin, Mikhail, additional, Bilchenko, Oleksandr, additional, Cherney, David Z I, additional, Chertow, Glenn M, additional, Douthat, Walter, additional, Dwyer, Jamie P, additional, Escudero, Elizabeth, additional, Pecoits-Filho, Roberto, additional, Furuland, Hans, additional, Górriz, José Luis, additional, Greene, Tom, additional, Haller, Hermann, additional, Hou, Fan Fan, additional, Kang, Shin-Wook, additional, Isidto, Rey, additional, Khullar, Dinesh, additional, Mark, Patrick B, additional, McMurray, John J V, additional, Kashihara, Naoki, additional, Nowicki, Michal, additional, Persson, Frederik, additional, Correa-Rotter, Ricardo, additional, Rossing, Peter, additional, Toto, Robert D, additional, Umanath, Kausik, additional, Van Bui, Pham, additional, Wittmann, István, additional, Lindberg, Magnus, additional, Sjöström, C David, additional, Langkilde, Anna Maria, additional, and Heerspink, Hiddo J L, additional

Published
2020
Full Text
View/download PDF

15. P1396EFFECT OF MIXED VERSUS ANIMAL-BASED LOW PHOSPHORUS DIETS IN DIALYSIS PATIENTS ON INTACT FGF23 LEVELS: A RANDOMIZED CLINICAL TRIAL

Author

Ramirez-Sandoval, Juan C, primary, Atilano-Carsi, Ximena, primary, Sánchez-Silva, Jorge, primary, Arce-Santander, Celene, primary, Cruz, Cristino, primary, Basulto-Sosa, Pamela, primary, Tamez-Pedroza, Luis, primary, García de León, Miguel, primary, Espinosa-Cuevas, Ángeles, primary, and Correa-Rotter, Ricardo, primary

Published
2020
Full Text
View/download PDF

17. Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers

Author

Schievink, Bauke, primary, de Zeeuw, Dick, additional, Smink, Paul A, additional, Andress, Dennis, additional, Brennan, John J, additional, Coll, Blai, additional, Correa-Rotter, Ricardo, additional, Hou, Fan Fan, additional, Kohan, Donald, additional, Kitzman, Dalane W, additional, Makino, Hirofumi, additional, Parving, Hans-Henrik, additional, Perkovic, Vlado, additional, Remuzzi, Giuseppe, additional, Tobe, Sheldon, additional, Toto, Robert, additional, Hoekman, Jarno, additional, and Lambers Heerspink, Hiddo J, additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results